The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Scalp Cooling to Prevent Chemo-induced Hair Loss
Official Title: Scalp Cooling for Alopecia Prevention (SCALP)
Study ID: NCT01986140
Brief Summary: Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.
Detailed Description: Cooling the scalp during chemotherapy may help reduce the chances of losing hair during treatment. The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device may stop patients who are undergoing chemotherapy from losing their hair.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Hematology & Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Texas Oncology - Medical City Dallas, Dallas, Texas, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
USOncology / Texas Oncology-Memorial City, Houston, Texas, United States
Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, Texas, United States
Name: Julie Nangia, M.D.
Affiliation: Baylor College of Medicine
Role: PRINCIPAL_INVESTIGATOR